Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | GALR3 | O60755 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 4/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10456507 | 0.87 | MAPT (0.38) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL4677043 | 0.85 | TSHR (0.37) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL11507622 | 0.82 | MAPT (0.36) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL16045620 | 0.82 | MAPT (0.36) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL6268593 | 0.81 | TSHR (0.34) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL33467 | 0.81 | TSHR (0.48) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL17266586 | 0.80 | MAPT (0.39) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL17088053 | 0.79 | FAAH (0.36) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL27805092 | 0.79 | TSHR (0.47) | TSHRCHRM2CHRM4CHRM1TBXA2R | |
| SCHEMBL28322566 | 0.79 | TSHR (0.47) | TSHRCHRM2CHRM4CHRM1TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | claimed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | claimed |
| EP-3661901-B1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEM CO (US) | 2023-12-06 | — | — | EP | disclosed |
| CN-110997605-B | Synthesis of diols by transfer hydrogenation of alpha-functionalized esters with alcohols | 伊士曼化工公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3661901-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | Eastman Chemical Company (US) | 2020-06-10 | — | — | EP | disclosed |
| CN-110997605-A | Synthesis of diols by transfer hydrogenation of α -functionalized esters with alcohols | 伊士曼化工公司 | 2020-04-10 | — | — | CN | disclosed |
| US-10266467-B2 | Synthesis of glycols via transfer hydrogenation of alpha-functional esters with alcohols | EASTMAN CHEMICAL COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2019027948-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEMICAL COMPANY (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190039978-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | EASTMAN CHEMICAL COMPANY (US) | 2019-02-07 | — | — | US | disclosed |
| CN-105175277-B | A kind of inhibitor of 3 GAPD and its preparation method and application | 中山大学肿瘤防治中心 | 2018-04-03 | — | — | CN | disclosed |
| CN-105175277-A | Inhibitor of glyceraldehyde-3-phosphate dehydrogenase, preparation method and application thereof | UNIV SUN YAT SEN CANCER CT | 2015-12-23 | — | — | CN | disclosed |
| US-8672145-B2 | Urea sorbent | FRESENIUS MEDICAL CARE HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | S.H. PHARMA., LTD (KR) | 2010-08-26 | — | — | US | disclosed |
| WO-2009045083-A2 | COMBINATION THERAPY FOR NEUROPROTECTION | S.H. PHARMA., LTD (KR) | 2009-04-09 | — | — | WO | disclosed |
| EP-0967230-B1 | Catalyst system for the preparation of olefin (co)polymers | BAYER AG (DE) | 2003-01-02 | — | — | EP | disclosed |
| US-6180554-B1 | ORGANOALUMINUM COMPOUND, GROUP IV-VI METAL COMPOUND, AND MONO-OR DIHALOCARBOXYLIC ACID ALKYL ESTER REACTIVATOR | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-30 | — | — | US | disclosed |
| EP-0967230-A1 | Catalyst system for the preparation of olefin (co)polymers | Bayer Aktiengesellschaft (DE) | 1999-12-29 | — | — | EP | disclosed |
| US-4922010-A | Processes for preparing 2-substituted propionic acid and derivatives thereof | UBE INDUSTRIES, LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190039978-A1 | SYNTHESIS OF GLYCOLS VIA TRANSFER HYDROGENATION OF ALPHA-FUNCTIONAL ESTERS WITH ALCOHOLS | ADH1A, ADH1C, ADH5 | TSHR 3066/4885CHRM2 3340/4885CHRM4 2956/4885 |
| US-10266467-B2 | Synthesis of glycols via transfer hydrogenation of alpha-functional esters with alcohols | ADH1A, ADH1C, ADH5 | TSHR 3066/4885CHRM2 3340/4885CHRM4 2956/4885 |
| US-20100216749-A1 | Combination Therapy for Neuroprotection | MPO, BDNF, NLN | TSHR 4770/4885CHRM2 1556/4885CHRM4 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.